GENE ONLINE|News &
Opinion
Blog

2022-12-14| In-DepthSpecial

A Force To Be Reckoned With – BioBetter Biologics

by GeneOnline
Share To
Off-patent biologics are a large market for ‘follow-on’ biologics. Biobetters, in particular, are novel innovations designed to be therapeutically more efficient and safer. They present a new market territory and have witnessed growing interest among drug manufacturers in recent years.

The marketing term ‘biobetter’ was coined in a Mumbai bio-conference in 2007 by Mr. GV Prasa, an Indian business executive, and has been markedly used ever since. Biobetters are novel highly-differentiated entities with strong bio-superiority over existing approved biologics. They are the result of cutting-edge research and novel chemical/molecular modifications (e.g. PEGylation/residue substitutions), and boast enhanced therapeutic benefits, such as improved potency and selectivity, increased bioavailability, longer half-life, and better safety.

GO Prime with only $1.49 now

LATEST
GeneOnline’s Weekly News Highlights: Nov 20-Nov 24
2023-11-27
SK Bioscience and Hilleman Laboratories Join Forces for Ebola Vaccine Development
2023-11-23
BeiGene to Expand Oncology Pipeline Through ENSEM Therapeutics Partnership
2023-11-23
Advancing the Frontiers of Cell and Gene Therapy – An Interview with Dr. Shin Kawamata
2023-11-21
Astellas and Pfizer’s Drug Receives FDA Approval as Treatment for High-Risk Prostate Cancer Recurrence
2023-11-21
GeneOnline’s Weekly News Highlights: Nov 13-Nov 17
2023-11-20
Singapore’s NUS Medicine Launches Centre for Sustainable Medicine
2023-11-20
EVENT
2023-11-30
2023 Healthcare+ EXPO・Taiwan
Taipei , Taiwan
Scroll to Top